title: When to harvest peripheral-blood stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood.
abstract: OBJECTIVE
  To evaluate whether the CD34+ yield from a single peripheral-blood stem-cell (PBSC) harvest could be predicted by measurement of the patient's circulating WBC and CD34+ cell concentrations on the day before harvest.
  
  
  METHODS
  Thirty-nine patients with hematologic or nonhematologic malignancy underwent 41 stem-cell mobilization episodes with cytotoxic chemotherapy and/or granulocyte colony-stimulating factor (G-CSF), and a total of 63 leukapheresis procedures were performed. Peripheral-blood samples were analyzed for WBC and CD34+ cell concentration both on the day before and the day of leukapheresis.
  
  
  RESULTS
  The median WBC and CD34+ concentrations on the day preceding leukapheresis were 10.0 x 10(9)/L (range, 0.4 to 44.4) and 24.9 x 10(6)/L (range, 0.1 to 349.4), respectively. On the day of harvest, the corresponding figures were 15.1 x 10(9)/L (range, 1.5 to 52.6) and 29.3 x 10(6)/L (range, 0.1 to 543.1), respectively. The median CD34+ cell number collected in a single leukapheresis was 2.6 x 10(6)/kg body weight (range, 0.1 to 26.1). Both the preceding day (r = .84, P < .001) and harvest day (r = .95, P < .001) CD34+ circulating concentrations correlated significantly with the number of CD34+ cells per kilogram collected at leukapheresis. The correlation between CD34+ cells per kilogram collected and harvest day WBC count was also significant (r = .43, P <.001), but with the preceding day WBC count was nonsignificant.
  
  
  CONCLUSIONS
  The number of CD34+ cells harvested in a single leukapheresis can be predicted by measurement of the preceding day peripheral-blood circulating CD34+ concentration, and on the basis of these data a table of probable CD34+ cell yield has been constructed. This correlation may facilitate the efficient organization of leukapheresis procedures.
authors.affiliation: Charing Cross Hospital, London, United Kingdom.
authors.forename: C
authors.initials: C
authors.lastname: Elliott
authors.forename: D M
authors.initials: DM
authors.lastname: Samson
authors.forename: S
authors.initials: S
authors.lastname: Armitage
authors.forename: M P
authors.initials: MP
authors.lastname: Lyttelton
authors.forename: D
authors.initials: D
authors.lastname: McGuigan
authors.forename: R
authors.initials: R
authors.lastname: Hargreaves
authors.forename: C
authors.initials: C
authors.lastname: Giles
authors.forename: G
authors.initials: G
authors.lastname: Abrahamson
authors.forename: Z
authors.initials: Z
authors.lastname: Abboudi
authors.forename: M
authors.initials: M
authors.lastname: Brennan
authors.forename: E J
authors.initials: EJ
authors.lastname: Kanfer
mesh_terms: D018952:Antigens, CD34 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002465:Cell Movement; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000097:blood / Q000473:pathology* / Q000628:therapy*; D006412:Hematopoietic Stem Cells / Q000276:immunology / Q000473:pathology; D006801:Humans; D007937:Leukapheresis; D007958:Leukocyte Count; D009369:Neoplasms / Q000097:blood / Q000473:pathology* / Q000628:therapy*; D012189:Retrospective Studies
chemical_list: D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor